Literature DB >> 33973185

How Prevalent Is Cancer in Confirmed Cases with Coronaviruses and Severe Acute Respiratory Syndromes?

Maryam Fotouhi1,2, Elham Samami1,3, Sahar Mohseni1,4, Amir Nasrollahizadeh1,2, Mohammad Haddadi1,2, Mona Mirbeyk1,2, Amene Saghazadeh1,5, Nima Rezaei6,7,8.   

Abstract

Novel coronavirus disease 2019 (COVID-19) has posed a crucial hazard to global health. The new species share similarities with the two previously emerged entities: severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS) that have caused outbreaks in 2002 and 2012, respectively. Interestingly, all of these coronaviruses can cause potentially fatal respiratory syndromes, though behave differently in patients with cancer compared to patients without cancer. Accordingly, the present chapter aims to, through a systematic investigation, estimate the prevalence of cancer among COVID-19, SARS, and MERS confirmed cases. Our analysis based on data from 78 studies with SARS, MERS, and COVID-19 confirmed cases showed that the prevalence of cancer (4.94%) stands at fourth place after hypertension (20.8%), diabetes (11.39%), and cardiovascular diseases (7.46%). According to the findings of the present study, comorbidities are significantly more common in patients with MERS compared to patients with COVID-19 and SARS, and this was the cancer case as well. Further studies need to address whether or not patients with coronaviruses and cancer are different from patients with coronaviruses without cancer in terms of clinical manifestations, laboratory findings, outcomes, and men to women ratio.

Entities:  

Keywords:  COVID-19; Cancer; Comorbidities; MERS; SARS; Systematic review

Mesh:

Year:  2021        PMID: 33973185     DOI: 10.1007/978-3-030-63761-3_17

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  18 in total

1.  All together to Fight COVID-19.

Authors:  Sara Momtazmanesh; Hans D Ochs; Lucina Q Uddin; Matjaz Perc; John M Routes; Duarte Nuno Vieira; Waleed Al-Herz; Safa Baris; Carolina Prando; Laszlo Rosivall; Amir Hamzah Abdul Latiff; Timo Ulrichs; Vasili Roudenok; Juan Carlos Aldave Becerra; Deepak B Salunke; Ekaterini Goudouris; Antonio Condino-Neto; Anzhela Stashchak; Oleksandr Kryvenko; Mykola Stashchak; Anastasia Bondarenko; Nima Rezaei
Journal:  Am J Trop Med Hyg       Date:  2020-06       Impact factor: 2.345

2.  COVID-19 and Cancer: Lessons From a Pooled Meta-Analysis.

Authors:  Aakash Desai; Sonali Sachdeva; Tarang Parekh; Rupak Desai
Journal:  JCO Glob Oncol       Date:  2020-04

3.  High-dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome.

Authors:  James C Ho; Gaik C Ooi; Thomas Y Mok; Johnny W Chan; Ivan Hung; Bing Lam; Poon C Wong; Patrick C Li; Pak L Ho; Wah K Lam; Chun K Ng; Mary S Ip; Kar N Lai; Moira Chan-Yeung; Kenneth W Tsang
Journal:  Am J Respir Crit Care Med       Date:  2003-08-28       Impact factor: 21.405

4.  Epidemiologic features of the first MERS outbreak in Korea: focus on Pyeongtaek St. Mary's Hospital.

Authors:  Kyung Min Kim; Moran Ki; Sung-Il Cho; Minki Sung; Jin Kwan Hong; Hae-Kwan Cheong; Jong-Hun Kim; Sang-Eun Lee; Changhwan Lee; Keon-Joo Lee; Yong-Shik Park; Seung Woo Kim; Bo Youl Choi
Journal:  Epidemiol Health       Date:  2015-09-17

Review 5.  The urgent need for integrated science to fight COVID-19 pandemic and beyond.

Authors:  Negar Moradian; Hans D Ochs; Constantine Sedikies; Michael R Hamblin; Carlos A Camargo; J Alfredo Martinez; Jacob D Biamonte; Mohammad Abdollahi; Pedro J Torres; Juan J Nieto; Shuji Ogino; John F Seymour; Ajith Abraham; Valentina Cauda; Sudhir Gupta; Seeram Ramakrishna; Frank W Sellke; Armin Sorooshian; A Wallace Hayes; Maria Martinez-Urbistondo; Manoj Gupta; Leila Azadbakht; Ahmad Esmaillzadeh; Roya Kelishadi; Alireza Esteghamati; Zahra Emam-Djomeh; Reza Majdzadeh; Partha Palit; Hamid Badali; Idupulapati Rao; Ali Akbar Saboury; L Jagan Mohan Rao; Hamid Ahmadieh; Ali Montazeri; Gian Paolo Fadini; Daniel Pauly; Sabu Thomas; Ali A Moosavi-Movahed; Asghar Aghamohammadi; Mehrdad Behmanesh; Vafa Rahimi-Movaghar; Saeid Ghavami; Roxana Mehran; Lucina Q Uddin; Matthias Von Herrath; Bahram Mobasher; Nima Rezaei
Journal:  J Transl Med       Date:  2020-05-19       Impact factor: 5.531

Review 6.  Lymphopenia in COVID-19: Therapeutic opportunities.

Authors:  Nazanin Fathi; Nima Rezaei
Journal:  Cell Biol Int       Date:  2020-06-03       Impact factor: 3.612

7.  COVID-19 and picotechnology: Potential opportunities.

Authors:  Navid Rabiee; Mohammad Rabiee; Mojtaba Bagherzadeh; Nima Rezaei
Journal:  Med Hypotheses       Date:  2020-06-01       Impact factor: 1.538

8.  A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster.

Authors:  Jasper Fuk-Woo Chan; Shuofeng Yuan; Kin-Hang Kok; Kelvin Kai-Wang To; Hin Chu; Jin Yang; Fanfan Xing; Jieling Liu; Cyril Chik-Yan Yip; Rosana Wing-Shan Poon; Hoi-Wah Tsoi; Simon Kam-Fai Lo; Kwok-Hung Chan; Vincent Kwok-Man Poon; Wan-Mui Chan; Jonathan Daniel Ip; Jian-Piao Cai; Vincent Chi-Chung Cheng; Honglin Chen; Christopher Kim-Ming Hui; Kwok-Yung Yuen
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

9.  The immune system as a target for therapy of SARS-CoV-2: A systematic review of the current immunotherapies for COVID-19.

Authors:  Amir Hossein Mansourabadi; Mona Sadeghalvad; Hamid-Reza Mohammadi-Motlagh; Nima Rezaei
Journal:  Life Sci       Date:  2020-08-01       Impact factor: 5.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.